Background:
The current standard of care for relapsed and refractory acute lymphoblastic leukemia (ALL) is combination chemotherapy.
Case presentation:
We report a case of highly refractory ALL who was treated with blinatumomab. The ALL in this patient relapsed within a month after completion of hyperCVAD regimen and was refractory to high dose mitoxantrone/cytarabine and CLAG regimens.
Conclusion:
This highly refractory pre-B Ph(-) ALL was induced to complete remission after one course of single agent blinatumomab.